Loading...
•
Jun 30, 2020
Enanta Pharmaceuticals Q3 2020 Earnings Report
Enanta Pharmaceuticals reported financial results for the third quarter of fiscal year 2020.
Key Takeaways
Enanta Pharmaceuticals reported a total revenue of $18.7 million, consisting of royalty revenue, for the three months ended June 30, 2020. The net loss for the quarter was $14.3 million, or a loss of $0.71 per diluted common share. The company's cash, cash equivalents, and marketable securities totaled $435.4 million at the end of the quarter.
Initiated Phase 1b Study of EDP-514 in Viremic HBV Patients and Resumed Phase 1b Study of EDP-514 in NUC-Suppressed HBV Patients
Plans to Initiate Two Phase 2 Studies of EDP-938 in Pediatric and Adult Transplant Patients with RSV in 4Q 2020
Initiated ARGON-2 Phase 2b Study of EDP-305 in Patients with NASH, On Track to Initiate Phase 1 Study of EDP-297 for NASH in 3Q 2020
Royalty Revenue for the Quarter was $18.7 Million
Revenue by Segment
Forward Guidance
Enanta plans to issue its fiscal fourth quarter financial results press release, and hold a conference call regarding those results, on November 23, 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...